Literature DB >> 1995647

Expression of biologically active human antithrombin III by recombinant baculovirus in Spodoptera frugiperda cells.

L S Gillespie1, K K Hillesland, D J Knauer.   

Abstract

Antithrombin III (ATIII) is a plasma-borne serine protease inhibitor that plays a pivotal role in the regulation of hemostasis. The cDNA for ATIII has been available, but genetic studies on the functional domains of ATIII have not progressed because of the absence of an expression system that will yield sufficient quantities of biologically active protein for biochemical analyses. In the present studies the cDNA of the human antithrombin III gene was inserted into the vector pVL 1393, which is suitable for cotransfection of Spodoptera frugiperda (Sf9) insect cells with Baculovirus wild-type DNA. Recombinant virus particles were selected by the presence of occlusion-negative plaques. Upon infection with purified recombinant virus, Sf9 cells secreted 10-35 micrograms of ATIII/1 x 10(6) cells. Southern analysis of DNA from infected cells demonstrated incorporation of the full-length cDNA into the Baculovirus recombinant, and RNase protection experiments verified the presence of full-length transcript. This recombinant ATIII protein was immunologically reactive with antisera raised against native human ATIII, formed stable complexes with thrombin, and was heparin-accelerated at the same concentration as native human ATIII. In addition, the recombinant ATIII retained specificity for the same molecular species of heparin that activates authentic human ATIII. This is the first successful production of active, recombinant ATIII in quantities that will allow purification on the milligram scale and permit a biochemical analysis of genetically engineered variants.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1995647

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  Decreased affinity of recombinant antithrombin for heparin due to increased glycosylation.

Authors:  I Björk; K Ylinenjärvi; S T Olson; P Hermentin; H S Conradt; G Zettlmeissl
Journal:  Biochem J       Date:  1992-09-15       Impact factor: 3.857

2.  Temporal transcription program of recombinant Autographa californica multiple nucleopolyhedrosis virus.

Authors:  Shih Sheng Jiang; I-Shou Chang; Lin-Wei Huang; Po-Cheng Chen; Chi-Chung Wen; Shu-Chen Liu; Li-Chu Chien; Chung-Yen Lin; Chao A Hsiung; Jyh-Lyh Juang
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

3.  Elimination of glycosylation heterogeneity affecting heparin affinity of recombinant human antithrombin III by expression of a beta-like variant in baculovirus-infected insect cells.

Authors:  E Ersdal-Badju; A Lu; X Peng; V Picard; P Zendehrouh; B Turk; I Björk; S T Olson; S C Bock
Journal:  Biochem J       Date:  1995-08-15       Impact factor: 3.857

4.  Recombinant human antithrombin expressed in the milk of non-transgenic goats exhibits high efficiency on rat DIC model.

Authors:  Hai Yang; Qing-Wang Li; Zeng-Sheng Han; Jian-Hong Hu; Wen-Ye Li; Zhi-Bin Liu
Journal:  J Thromb Thrombolysis       Date:  2009-05-20       Impact factor: 2.300

5.  Mutation of the H-helix in antithrombin decreases heparin stimulation of protease inhibition.

Authors:  Patrick R Gonzales; Timothy D Walston; Laureano O Camacho; Dana M Kielar; Frank C Church; Alireza R Rezaie; Scott T Cooper
Journal:  Biochim Biophys Acta       Date:  2007-08-30

6.  Efficient single step chromatographic purification of recombinant human antithrombin (rhAT) from Saccharomyces cerevisiae.

Authors:  Maheswara Reddy Mallu; Sandeep Vemula; Srinivasa Reddy Ronda
Journal:  3 Biotech       Date:  2016-05-17       Impact factor: 2.406

7.  Comparison of biological activities of human antithrombins with high-mannose or complex-type nonfucosylated N-linked oligosaccharides.

Authors:  Tsuyoshi Yamada; Yutaka Kanda; Makoto Takayama; Akitoshi Hashimoto; Tsutomu Sugihara; Ai Satoh-Kubota; Eri Suzuki-Takanami; Keiichi Yano; Shigeru Iida; Mitsuo Satoh
Journal:  Glycobiology       Date:  2016-01-07       Impact factor: 4.313

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.